Last updated: September 26, 2026
PRAVACHOL, the brand name for pravastatin sodium, is a mature cardiovascular product whose commercial value shifted from branded prescription sales to low-cost generic volume after U.S. patent and regulatory exclusivity ended in 2006. Bristol-Myers Squibb’s branded revenue declined sharply after generic entry, while pravastatin remained clinically relevant as a lower-interaction statin used in hyperlipidemia and cardiovascular-risk reduction. The product has no meaningful current biosimilar risk, limited remaining patent leverage, and low commercial attractiveness for branded innovation.
Pravachol Patent Landscape, Market Dynamics, and Financial Trajectory
What is Pravachol and who markets it?
Pravachol is pravastatin sodium, an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol and cardiovascular risk. Bristol-Myers Squibb commercialized Pravachol in the United States after licensing rights from Sankyo, now part of Daiichi Sankyo.
| Product attribute |
Detail |
| Active ingredient |
Pravastatin sodium |
| Drug class |
Statin, HMG-CoA reductase inhibitor |
| Original developer |
Sankyo |
| Major U.S. commercializer |
Bristol-Myers Squibb |
| U.S. approval |
1991 |
| Dosage forms |
Oral tablets; historically 10 mg, 20 mg, 40 mg and 80 mg strengths |
| Main indications |
Hypercholesterolemia, mixed dyslipidemia, primary and secondary cardiovascular-risk reduction |
| Current commercial status |
Mature generic product |
| Biosimilar exposure |
None; pravastatin is a synthetic small molecule |
The product gained market acceptance partly because pravastatin has limited cytochrome P450 3A4 metabolism compared with several competing statins. That pharmacologic profile supported use in patients receiving multiple medicines, although newer high-intensity statins such as atorvastatin and rosuvastatin offer greater LDL-cholesterol reduction.
When did Pravachol lose exclusivity?
Pravachol lost practical U.S. market exclusivity in 2006, when generic pravastatin products entered the market after expiration of the principal patent and associated regulatory protections.
| Milestone |
Approximate timing |
Commercial effect |
| U.S. approval |
1991 |
Launch of branded pravastatin |
| Peak branded expansion |
Late 1990s to early 2000s |
Broad primary-care use |
| Principal patent protection |
Ended in the mid-2000s |
Generic filing and launch risk increased |
| Generic entry |
2006 |
Rapid branded-price and volume erosion |
| Post-exclusivity period |
2007 onward |
Pravastatin became a mature generic medicine |
The commonly cited U.S. patent protection endpoint for Pravachol was April 2006. Patent timing was affected by the applicable patent term, regulatory extensions and litigation-related generic-entry arrangements. The commercial result was clear: once multiple generic suppliers entered, the branded product lost pricing power.
What patents protected Pravachol?
The core patent estate protected pravastatin and related pharmaceutical compositions. The principal U.S. patent historically associated with pravastatin was U.S. Patent No. 4,346,227, assigned to Sankyo and licensed for U.S. commercialization.
| Patent category |
Historical relevance |
Current value |
| Pravastatin compound protection |
Covered the active statin molecule and related compounds |
Expired |
| Pharmaceutical composition claims |
Covered dosage forms containing pravastatin |
Expired or commercially ineffective |
| Method-of-use claims |
Supported cholesterol-treatment indications |
Expired or difficult to enforce against broad generic use |
| Manufacturing claims |
Could cover production or purification processes |
Limited value where non-infringing processes are available |
| Pediatric or regulatory extension |
Extended the effective period of protection in the United States |
Expired |
The commercially important protection was compound-level protection. Formulation and method-of-use claims did not preserve a durable branded franchise after generic manufacturers could market standard pravastatin tablets.
How many patents currently cover Pravachol?
No active patent estate appears to provide meaningful market exclusivity for the original Pravachol product in the United States. Historical Orange Book-listed patents and associated exclusivity periods have expired.
The current patent position is therefore different from the situation during the branded product’s growth period:
- The original compound patent is expired.
- Formulation protection no longer prevents routine generic pravastatin tablets.
- Method-of-use protection is not a practical barrier to ordinary generic substitution.
- Manufacturing patents, if held for particular processes, would not block all pravastatin products.
- No new patent-based lifecycle strategy has restored Pravachol brand exclusivity.
A definitive current patent count would require a live review of the FDA Orange Book, USPTO records and jurisdiction-specific patent databases. The commercial conclusion does not depend on that count: Pravachol is no longer protected by a patent position capable of sustaining branded pricing.
What is the Orange Book status of Pravachol?
The FDA Orange Book historically listed Pravachol-related patents and generic equivalents after abbreviated new drug applications were approved. Today, pravastatin tablets are primarily supplied through abbreviated new drug applications rather than through a protected branded franchise.
The Orange Book has commercial importance for:
- Identifying listed patents at the time of generic filing.
- Tracking Paragraph IV certifications.
- Recording generic approvals and therapeutic-equivalence codes.
- Establishing the reference listed drug for generic pravastatin tablets.
Because the relevant patents expired years ago, Orange Book activity for pravastatin is now more important for product identification and generic substitution than for litigation-driven exclusivity.
Which companies challenged Pravachol patents?
Generic manufacturers, including major U.S. and international suppliers, pursued pravastatin opportunities as patent expiry approached. The competitive field included companies such as Apotex, Teva, Mylan, Sandoz and Ranbaxy, although the participants and timing varied by strength, formulation and jurisdiction.
The most commercially significant challenge was the overall generic-entry campaign rather than a continuing single-company patent dispute. Once generic competition became available, several suppliers could compete on price, pharmacy contracts and wholesaler access.
What Paragraph IV challenges affected Pravachol?
Paragraph IV certifications permit a generic applicant to assert that a listed patent is invalid, unenforceable or not infringed. Pravastatin was subject to the standard Hatch-Waxman generic-entry process, including patent certifications and litigation risk as the principal protection period approached.
The practical significance of those challenges ended after:
- The principal patents expired.
- Generic approvals accumulated.
- Multiple manufacturers obtained market access.
- The brand lost the ability to sustain a substantial price premium.
Any historical settlement terms would need to be reviewed in individual court dockets and regulatory records. They no longer create a meaningful barrier to generic pravastatin supply.
What was Pravachol’s financial trajectory?
Pravachol became a major cardiovascular product for Bristol-Myers Squibb before facing direct generic erosion. Company filings placed annual global sales in the billion-dollar range during the product’s mature branded period. Sales declined as physicians gained access to newer statins and as generic competition approached.
| Period |
Financial position |
Principal drivers |
| 1990s |
Rapid growth |
Expansion of statin prescribing and primary-care use |
| Early 2000s |
Peak or near-peak branded revenue |
Large treated population and established safety profile |
| 2004-2005 |
Decline before full generic erosion |
Competition from Lipitor, Zocor and other statins; patent-risk discounting |
| 2006 |
Sharp transition |
Generic pravastatin launches |
| 2007 onward |
Branded revenue collapse |
Substitution, price compression and reduced promotional support |
| Current market |
Low-margin generic business |
Commodity competition and stable clinical demand |
Bristol-Myers Squibb’s annual reports show Pravachol revenue at approximately the billion-dollar level before generic entry. The exact reported amount varied by year and geographic accounting treatment. After generic launch, the brand’s economic profile changed from a high-margin primary-care product to a low-volume residual brand.
The key financial event was not a gradual decline in medical demand. Cholesterol treatment continued to expand. The value transfer occurred because generic manufacturers captured prescription volume and reduced net pricing.
How did Pravachol compare with competing statins?
Pravachol’s commercial position weakened because its LDL-lowering potency and dose flexibility were less competitive than those of atorvastatin and rosuvastatin.
| Drug |
Brand |
Relative commercial position |
Main competitive characteristic |
| Pravastatin |
Pravachol |
Mature generic |
Lower interaction potential; moderate potency |
| Atorvastatin |
Lipitor |
Historically dominant statin |
High potency and broad dose range |
| Simvastatin |
Zocor |
Major earlier competitor |
Strong historical uptake and low cost after generic entry |
| Rosuvastatin |
Crestor |
High-potency competitor |
Strong LDL reduction and premium positioning before generic entry |
| Lovastatin |
Mevacor |
Older generic statin |
Earlier-generation alternative |
Pravastatin retained a niche where clinicians valued its tolerability, interaction profile or use in patients requiring a moderate-intensity statin. It did not retain substantial pricing power against generic atorvastatin, simvastatin and other low-cost alternatives.
What formulation patents protect Pravachol?
No formulation patent currently blocks ordinary generic pravastatin tablets. The original commercial product used conventional oral tablets, which are relatively difficult to protect after compound-patent expiration because generic manufacturers can reproduce the dosage form through standard pharmaceutical processes.
Potential formulation claim categories historically included:
- Tablet compositions containing pravastatin sodium.
- Stability and excipient combinations.
- Dose-specific formulations.
- Manufacturing and granulation processes.
- Packaging or storage configurations.
These categories can support incremental protection for some pharmaceutical products. For Pravachol, they did not create a durable post-expiry barrier because the core tablet was simple, established and readily substitutable.
What method-of-use patents covered Pravachol?
Pravachol’s labeled uses included treatment of hypercholesterolemia and cardiovascular-risk reduction. Method-of-use claims may have covered treatment populations or therapeutic applications, but they did not preserve meaningful exclusivity after the primary indication was broadly established and the relevant patents expired.
Generic pravastatin labels could support substitution for the reference product where FDA therapeutic-equivalence standards were met. Physicians could also prescribe generic pravastatin for the same clinical purposes without relying on the branded product.
What FDA regulatory status does Pravachol have?
Pravachol is an FDA-approved reference product, while generic pravastatin tablets are approved through the abbreviated new drug application pathway. Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.
The regulatory landscape has several implications:
- No new clinical-efficacy program is required for each conventional generic tablet.
- FDA therapeutic-equivalence ratings support pharmacy substitution under state law.
- The reference product retains historical regulatory importance but not pricing power.
- Approval of multiple strengths increases generic availability.
- Regulatory barriers are materially lower than for biologics or complex drug-delivery systems.
Is there biosimilar risk for Pravachol?
There is no biosimilar risk because pravastatin is a small-molecule chemical drug, not a biologic. The relevant competitive threat is generic substitution through the ANDA pathway.
This distinction matters commercially:
- Biosimilars require biologic comparability and often face manufacturing complexity.
- Pravastatin generics rely on conventional pharmaceutical equivalence and bioequivalence.
- Manufacturing is widely available.
- Supplier switching is relatively easy for wholesalers and pharmacies.
- Price competition is stronger than in many biologic markets.
What generic entry risks exist for Pravachol?
The generic-entry risk is effectively realized rather than prospective. The product has experienced the main stages of generic erosion:
- Pre-expiry price and formulary pressure.
- Initial generic launches.
- Rapid increase in generic market share.
- Decline in branded prescriptions.
- Long-term price compression.
- Consolidation around a limited group of cost-efficient suppliers.
Residual risks include manufacturing interruptions, drug shortages, wholesaler concentration and reimbursement changes. Those risks affect supply and margins rather than the existence of generic competition.
What licensing deals affected Pravachol?
The principal strategic transaction was Sankyo’s licensing arrangement with Bristol-Myers Squibb for commercialization in the United States. That relationship allowed Bristol-Myers Squibb to build a large branded cardiovascular franchise without originating the molecule internally.
The value of the arrangement declined after patent expiry. Royalty economics, if applicable under the underlying agreement, would have been pressured by lower branded sales and the transition to generic supply. The original licensing structure has limited relevance to today’s generic market unless residual rights or jurisdiction-specific agreements remain in force.
What patent litigation affects Pravachol?
No active patent litigation appears to have commercial significance for the original Pravachol product. Historical disputes centered on generic entry, patent validity, infringement and timing. Those cases mattered before and around the 2006 transition, not as an ongoing barrier to supply.
Current litigation risk is more likely to involve:
- Generic manufacturing quality.
- Product liability.
- Antitrust or channel practices.
- Drug-shortage allocation.
- Contract disputes between suppliers and purchasers.
Those issues do not restore exclusivity to the branded product.
How strong is the Pravachol patent estate?
The current patent estate is weak from a commercial-exclusivity perspective.
| Factor |
Assessment |
| Compound protection |
Expired |
| Formulation protection |
No meaningful blocking position |
| Method-of-use protection |
Expired or commercially limited |
| Manufacturing protection |
Potentially narrow and non-blocking |
| Orange Book leverage |
Historical rather than current |
| Generic substitution risk |
Very high |
| Branded pricing power |
Minimal |
| Lifecycle-management potential |
Low |
The product’s remaining value is based on clinical familiarity, manufacturing capability, distribution and generic procurement relationships. Patent strength no longer drives value.
What is the competitive landscape and revenue exposure?
Pravastatin competes in a large but heavily commoditized statin market. Generic atorvastatin and rosuvastatin typically capture greater value because they offer high-intensity LDL reduction. Pravastatin remains relevant in moderate-intensity treatment and in patients for whom interaction concerns influence prescribing.
For Bristol-Myers Squibb, the financial exposure was substantial at the time of expiry because Pravachol was a billion-dollar-scale product. The subsequent revenue loss was amplified by:
- High generic substitution rates.
- Lower reimbursement for branded pravastatin.
- Limited differentiation in the tablet formulation.
- Stronger clinical positioning of newer statins.
- Reduced need for branded sales promotion.
For current investors, Pravachol should be treated as a historical revenue contributor, not a material growth asset.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are low relative to biologics, inhaled products and complex injectables. Pravastatin tablets use established chemistry and conventional oral solid-dose manufacturing.
Remaining barriers may include:
- Reliable active pharmaceutical ingredient supply.
- Compliance with FDA current good manufacturing practice requirements.
- Validated impurity controls.
- Stability and packaging specifications.
- Commercial scale and procurement economics.
- Ability to maintain uninterrupted supply at low prices.
These are execution barriers, not durable IP barriers. A manufacturer with an efficient supply chain can compete without acquiring rights to the original Pravachol brand.
What are the likely generic launch scenarios?
Because generic launch already occurred, the relevant scenarios concern market structure rather than first entry.
| Scenario |
Likely outcome |
| Several suppliers remain active |
Stable low prices and broad pharmacy substitution |
| Supplier consolidation |
Higher shortage risk and modest price recovery |
| Brand retains limited prescriptions |
Small residual premium market |
| New formulation entrant |
Limited upside unless clinically differentiated |
| Manufacturing disruption |
Temporary price increases and sourcing changes |
A new branded pravastatin product would face high hurdles. It would need a clear benefit, such as improved adherence, a differentiated delivery system or a clinically meaningful interaction advantage, while competing against inexpensive established generics.
Key Takeaways
- Pravachol is pravastatin sodium, originally commercialized by Bristol-Myers Squibb under rights from Sankyo.
- The product was approved in the United States in 1991.
- Its principal U.S. exclusivity ended in the mid-2000s, with generic entry in 2006.
- Branded sales reached approximately the billion-dollar range before patent expiry.
- Generic entry caused a rapid and lasting collapse in branded revenue.
- The current market is generic, price-sensitive and operationally driven.
- No biosimilar issue exists because pravastatin is a small molecule.
- No active patent position appears capable of blocking standard generic pravastatin tablets.
- Pravachol retains clinical relevance but has little remaining patent or branded-growth value.
- The main current risks concern supply reliability, manufacturing quality and generic-market concentration.
FAQs About Pravachol Market and Patent Status
Is Pravachol still sold under the brand name?
Pravachol may remain available in limited markets or through residual branded channels, but pravastatin is primarily supplied as a generic medicine. Brand availability varies by country and distributor.
Did Bristol-Myers Squibb develop pravastatin?
No. Pravastatin originated with Sankyo. Bristol-Myers Squibb commercialized Pravachol in the United States through licensing and commercial rights arrangements.
Is pravastatin more profitable than atorvastatin today?
Generally no. Both are generic statins, but atorvastatin has broader use and higher potency. Profitability depends mainly on manufacturing cost, contracts, supplier concentration and market share.
Can a company launch a new Pravachol generic without a clinical trial?
A conventional generic applicant can generally use the FDA ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than repeat the originator’s full clinical-efficacy program.
Does Pravachol have any remaining value for licensing?
The original brand has limited licensing value. Opportunities would depend on geographic rights, supply agreements, differentiated formulations or combination products rather than on the expired core pravastatin patent estate.
References
-
Bristol-Myers Squibb Company. (2005). 2005 annual report. Bristol-Myers Squibb.
-
Bristol-Myers Squibb Company. (2006). 2006 annual report. Bristol-Myers Squibb.
-
Daiichi Sankyo Co., Ltd. (2024). Company history and pharmaceutical product information. Daiichi Sankyo.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (1982). U.S. Patent No. 4,346,227. U.S. Department of Commerce.
